Bisphosphonates Facing Riskier Committee As FDA Adds Esophageal Cancer To Advisory Panel Agenda
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA revises topics for September committee two weeks after announcing the meeting.
You may also be interested in...
Bisphosphonate Cancer Risk Divides FDA Officials Ahead Of Advisory Committee
FDA will ask panel whether potential long-term risks of the osteoporosis drugs could be avoided through a "drug holiday."
Bisphosphonate Cancer Risk Divides FDA Officials Ahead Of Advisory Committee
FDA will ask panel whether potential long-term risks of the osteoporosis drugs could be avoided through a "drug holiday."
Safety of Bisphosphonates To Be Reviewed By FDA Advisory Committees
The Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committees will meet Sept. 9 to review the safety of long-term use of bisphosphonates in treating osteoporosis.